1. Introduction {#sec1}
===============

The local anesthetic bupivacaine is a racemic mixture of S(−)- and R(+)-enantiomers. Racemic bupivacaine has biphasic vasoactivities, namely, vasoconstriction at a low concentration and vasodilatation at a high concentration \[[@B1]\]. Since 1976, when Aps and Reynolds showed this vasoactivity in a double-blind trial with forearm skin color changes of 31 volunteers \[[@B1]\], these vasoactivities have been further demonstrated using various *in vivo* methods with various animals or humans, such as television microscopy in rat cremaster muscle microvasculatures \[[@B2]\], intravital microscopy through a spinal window in dog pial vasculatures \[[@B3]\], laser Doppler imaging in human skin \[[@B4]\], as well as other techniques. Although inhibition of sympathetic nerves innervating arteries by racemic bupivacaine could not be ignored in *in vivo* studies, some *in vitro* studies with isolated preparations from human umbilical arteries \[[@B5]--[@B7]\], rat uterine arteries \[[@B8]\], and human uterine arteries \[[@B9]\] have confirmed that the vasoactivities are produced by direct actions of racemic bupivacaine itself on the arteries.

S(−)-bupivacaine was developed as an alternative long-acting local anesthetic with a clinical profile similar to that of racemic bupivacaine but with a lower potential for producing systemic toxicity \[[@B10]\]. S(−)-bupivacaine also has biphasic vasoactivities similar to those of racemic bupivacaine, which has been shown in*in vivo* studies \[[@B4], [@B11]--[@B13]\]. Furthermore, some of the *in vivo* studies have shown that R(+)-bupivacaine produced a dose-dependent vasodilatation \[[@B11], [@B13]\]. However, there is little information on the direct vasoactivities of S(−)- and R(+)-bupivacaine based on *in vitro* study. In this study, we investigated the vasocontractile activities of these agents using isolated rat aorta.

2. Methods {#sec2}
==========

2.1. Animals {#sec2.1}
------------

The experimental protocol was approved by the institutional animal care committee of Asahi University. Male Wistar rats weighing 240--280 g were used.

2.2. Functional Experiments {#sec2.2}
---------------------------

Rats were killed by decapitation under sevoflurane anesthesia, and the thoracic aorta was isolated and removed \[[@B14]\]. The thoracic aorta was placed in Krebs-Henseleit solution (mM; NaCl 118, KCl 4.7, NaHCO~3~ 25, KH~2~PO~4~ 1.2, MgSO~4~ 1.2, CaCl~2~ 2.5, and glucose 10; pH 7.4). Aortic rings were carefully prepared under a dissecting microscope, and then each intact ring was carefully pulled by wires in an organ chamber containing 5 mL Krebs-Henseleit solution bubbled with 95% O~2~ and 5% CO~2~ at 37°C. After a resting tension of 1.0 g was applied during one-hour equilibration period, changes in the tension were recorded isometrically when S(−)-bupivacaine, R(+)-bupivacaine, or racemic bupivacaine was cumulatively applied. Contractions were expressed as mg contractile tension.

2.3. Chemicals {#sec2.3}
--------------

S(−)-bupivacaine and R(+)-bupivacaine were generously donated by Maruishi Pharmaceutical (Osaka, Japan), and pseudoracemic bupivacaine was prepared by mixing with S(−)-bupivacaine and R(+)-bupivacaine at a ratio of 1 : 1 \[[@B15]\].

2.4. Statistical Analysis {#sec2.4}
-------------------------

The results are expressed as mean ± SD. The maximum response (E~max~\\) and the concentration producing a half-maximal response (EC~50~) were determined by Finley\'s probit analysis. Significance of differences was analyzed by Kruskal-Wallis test and Scheffé method as a post hoc comparison for multiple comparisons at a significance level of  0.05.

3. Results {#sec3}
==========

S(−)-bupivacaine, R(+)-bupivacaine, and racemic bupivacaine produced a biphasic response in the aortic rings, namely, concentration-dependent contraction from 10 *μ*M to 1 mM and relaxation at higher concentrations (*n* = 8, [Figure 1](#fig1){ref-type="fig"}.) The vasocontractile responses produced by S(−)-bupivacaine and racemic bupivacaine were significantly stronger than those by R(+)-bupivacaine. Furthermore, there were significant differences among E~max~ or EC~50~ of each bupivacaine ([Table 1](#tab1){ref-type="table"}).

4. Discussion {#sec4}
=============

As there has been only limited study of the direct vasoactivities of two bupivacaine enantiomers, S(−)- and R(+)-bupivacaine, we compared the vasocontractile effects of these two agents with that of racemic bupivacaine in this study. S(−)-bupivacaine showed the strongest E~max~ of the three agents, while R(+)-bupivacaine showed limited vasoconstriction. Although racemic bupivacaine produced as much E~max~ as S(−)-bupivacaine statistically ([Table 1](#tab1){ref-type="table"}), the activity level of racemic bupivacaine was located between those of S(−)-bupivacaine and R(+)-bupivacaine graphically ([Figure 1](#fig1){ref-type="fig"}). R(+)-bupivacaine, which produced small vasoconstriction even at high concentration, may interfere with vasoconstriction by S(−)-bupivacaine in racemic bupivacaine, which consists of the two enantiomers. Several *in vitro* studies have been done on racemic bupivacaine\'s direct vasoactivities. It has been reported that racemic bupivacaine contracted isolated rat uterine arteries \[[@B8]\], human uterine arteries \[[@B9]\], human umbilical arteries \[[@B5]--[@B7]\], and veins \[[@B6]\] in various degrees. Different vasocontractile activities of the enantiomers among the vessels might be, at least, a cause of the variety.

S(−)-bupivacaine produced the strongest vasoconstriction of the three bupivacaines in our study. Considering that the clinical use of S(−)-bupivacaine is increasing because of its lower toxicity \[[@B10]\], it is important to note that it may produce greater vasoconstriction than racemic bupivacaine does. Bupivacaine administered for epidural anesthesia raises the intrathecal and plasma concentration \[[@B16]\] and might contract several important vessels, including the pial, epidural, uterine, umbilical arteries, as well as others, with subsequent decrease of blood flow.

![Changes in vascular tension provoked by S(−)-, R(+)-, and racemic bupivacaines. \*:  *P* \< .05 versus R(+)-bupivacaine. *n* = 8.](ARP2010-820186.001){#fig1}

###### 

EC~50~ values and maximum contraction by bupivacaines.

  Bupivacaine   EC~50~(×10^−5^)   E~max~ (g)
  ------------- ----------------- ---------------
  S (−)         7.3 ± 2.9         0.31 ± 0.06
  R (+)         4.1 ± 4.0\*       0.12 ± 0.10\*
  Racemic       4.1 ± 1.6\*       0.21 ± 0.10

\*：*P* \< .05 versus S(−). *n* = 8.
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